Option chain shows key data for Oncotelic Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Oncotelic Therapeutics.

Oncotelic Therapeutics (OTC:OTLC) Stock, Option Chain

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Screenshot 2025-04-14 at 5.36.28 PM

Biotech

General

OTLC

Oncotelic&#39;s ASO Platform Could Mark A New Era In RNA Therapeutics

Screenshot 2025-03-20 at 5.33.44 PM

CELG

Oncotelic Inks Potentially Game-Changing Deal With Shanghai Medicilon

Screenshot 2024-05-31 at 8.39.16 PM

This Biotech Company&#39;s Lead Candidate Treats Rare Cancers As Well As Covid-19

ONCOTELIC THERAPEUTCS INC by Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics Inc

Press Releases

ONCOTELIC PRESENTATION AT PRECISION IN DRUG DISCOVERY & PRECLINICAL SUMMIT SAN DIEGO 2024

ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS

ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024

Oncotelic Therapeutics Implements PDAOAI Platform

Oncotelic CEO Vuong Trieu to Present Groundbreaking Research on Transforming Growth Factor Beta 2 (TGFB2) at SWCR 2025 Conference

Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon

Oncotelic Therapeutics Announces Successful Completion of Phase 1 Trial of OT-101 and IL-2, Highlights Findings at SWCR 2025 Conference

Oncotelic Therapeutics Publishes New Research Demonstrating Positive Prognostic Impact of Methylated TGFB2 and MGMT in Adult Glioblastoma Patients, Introduces Interactive PDAOAI

Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023

Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm

Oncotelic Therapeutics

Screenshot 2024-05-28 at 5.34.55 PM

News

CPMV

IOVA

Oncotelic Therapeutics (OTC: OTLC) Inks Deal With Mosaic ImmunoEngineering To Sell Clinical-Stage Necroptosis Cancer Therapy Assets

Screenshot 2024-04-08 at 5.30.32 PM

With Rise In Pancreatic Cancer, Oncotelic Therapeutics (OTCQB: OTLC) Opens Up Enrollment For STOP-PC Clinical Trial

Screenshot 2024-02-20 at 6.43.25 PM

Oncotelic Therapeutics Shares Groundbreaking Discovery In Pediatric Brainstem Tumors Demonstrating Potential For New Cancer Immunotherapy Treatments

Comments

Oncotelic Therapeutics

Oncotelic Therapeutics (OTLC) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell